Trends Immunol. 2026 Mar 11:S1471-4906(26)00038-4. doi: 10.1016/j.it.2026.02.007. Online ahead of print.
ABSTRACT
Li et al. described a tumor-derived neuroimmune mechanism that promotes clearance of established amyloid pathology in Alzheimer’s disease. secreted cystatin C activates TREM2-dependent microglial phagocytosis, reducing plaques and improving cognition. This work introduces a context-dependent neuroimmune-modulatory strategy that shifts Alzheimer’s therapy from broad immune activation toward substrate-coupled amyloid clearance.
PMID:41820136 | DOI:10.1016/j.it.2026.02.007